In vitro killing of multidrug/extensively drug-resistant Pseudomonas aeruginosa by fosfomycin alone or in combination with antipseudomonal antibiotics

References

• Pagani L, Mantengoli E, Migliavacca R, et al. Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the per-1 extended-spectrum β-lactamase in Northern Italy. J Clin Microbiol. 2004;42(6):2523–2529.
   PubMed Web of Science ®Google Scholar
• Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Res. 2019;8:1371.
   Google Scholar
• Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother. 2006;50(1):43–48.
   PubMed Web of Science ®Google Scholar
• Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002;34(5):634–640.
   PubMed Web of Science ®Google Scholar
• Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol. 2011;2:65.
   PubMed Web of Science ®Google Scholar
• Pournaras S, Maniati M, Spanakis N, et al. Spread of efflux pump-overexpressing, non-metallo-β-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. J Antimicrob Chemother. 2005;56(4):761–764.
   PubMed Web of Science ®Google Scholar
• Walsh CC, Landersdorfer CB, McIntosh MP, et al. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J Antimicrob Chemother. 2016;71(8):2218–2229.
   PubMed Web of Science ®Google Scholar
• Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis. 2012;31(5):695–701.
   PubMed Web of Science ®Google Scholar
• Walsh CC, McIntosh MP, Peleg AY, et al. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 2015;70(11):3042–3050.
   PubMed Web of Science ®Google Scholar
• Memar Y, Adibkia M, Farajnia K, et al. In-vitro effect of imipenem, fosfomycin, colistin, and gentamicin combination against carbapenem-resistant and biofilm-forming Pseudomonas aeruginosa isolated from burn patients. Iran J Pharm Res. 2021;20(2):286–296.
   PubMed Web of Science ®Google Scholar
• Avery LM, Sutherland CA, Nicolau DP. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa. J Med Microbiol. 2019;68(6):893–897.
   PubMed Web of Science ®Google Scholar
• Buisson Y, Bercion R, Mauclère P, et al. Preliminary study of the antagonistic effects between fosfomycin and beta-lactams on Pseudomonas aeruginosa observed on the antibiogram. Pathol Biol (Paris). 1988;36(5 Pt 2):671–674.
   PubMedGoogle Scholar
• Reguera JA, Baquero F, Berenguer J, et al. Beta-lactam-fosfomycin antagonism involving modification of penicillin-binding protein 3 in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34(11):2093–2096.
   PubMed Web of Science ®Google Scholar
• Pruekprasert P, Tunyapanit W. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa. Southeast Asian J Trop Med Public Health. 2005;36(5):1239–1242.
   PubMedGoogle Scholar
• Cuba GT, Rocha-Santos G, Cayô R, et al. In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2020;75(7):1874–1878.
   PubMed Web of Science ®Google Scholar
• Kastoris AC, Rafailidis PI, Vouloumanou EK, et al. Synergy of fosfomycin with other antibiotics for gram-positive and gram-negative bacteria. Eur J Clin Pharmacol. 2010;66(4):359–368.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Neely MN, Yamada WM, et al. The combination of fosfomycin plus meropenem is synergistic for Pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. Antimicrob Agents Chemother. 2018;62(12):18. e01682
   Web of Science ®Google Scholar
• MacLeod DL, Velayudhan J, Kenney TF, et al. Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(3):1529–1538.
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Barker LM, Sutherland JL, et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother. 2009;64(4):829–836.
   PubMed Web of Science ®Google Scholar
• Yamada S, Hyo Y, Ohmori S, et al. Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa. Chemotherapy. 2007;53(3):202–209.
   PubMed Web of Science ®Google Scholar
• Figueredo VM, Neu HC. Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis. J Antimicrob Chemother. 1988;22(1):41–50.
   PubMed Web of Science ®Google Scholar
• Antonello RM, Principe L, Maraolo AE, et al. Fosfomycin as partner drug for systemic infection management. A systematic review of its synergistic properties from in vitro and in vivo studies. Antibiotics. 2020;9(8):500.
   Google Scholar
• Monogue ML, Nicolau DP. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. J Antimicrob Chemother. 2018;1:942–952.
   Google Scholar
• Jahan S, Davis H, Ashcraft DS, et al. Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase–producing Pseudomonas aeruginosa using etest and time-kill assay. J Investig Med. 2021;69(2):371–376.
   PubMed Web of Science ®Google Scholar
• Mikhail S, Singh NB, Kebriaei R, et al. Evaluation of the synergy of Ceftazidime-Avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(8):e00779–19.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Zeiser ET, Becka SA, et al. Ceftazidime-Avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa. J Infect Dis. 2019;220(4):666–676.
   PubMed Web of Science ®Google Scholar
• Olsson A, Wistrand-Yuen P, Nielsen EI, et al. Efficacy of antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in automated time-lapse microscopy and static time-kill experiments. Antimicrob Agents Chemother. 2020;64(6):e02111. 19.
   PubMed Web of Science ®Google Scholar
• Avery LM, Nicolau DP. Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. J Antimicrob Chemother. 2018;73(8):2264–2265.
   PubMed Web of Science ®Google Scholar
• White RL, Burgess DS, Manduru M, et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40(8):1914–1918.
   PubMed Web of Science ®Google Scholar
• Brennan-Krohn T, Kirby JE. Antimicrobial synergy testing by the inkjet printer-assisted automated checkerboard array and the manual time-kill method. J Vis Exp. 2019;14:e58636.
   Google Scholar
• Giamarellos-Bourboulis EJ, Kentepozidis N, Antonopoulou A, et al. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2005;51(2):113–117.
   PubMed Web of Science ®Google Scholar
• Sardelic S, Bedenic B, Colinon-Dupuich C, et al. Infrequent finding of Metallo-Lactamase VIM-2 in carbapenem-resistant Pseudomonas aeruginosa strains from Croatia. Antimicrob Agents Chemother. 2012;56(5):2746–2749.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing, document M100. 30th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.
   Google Scholar
• López-Montesinos I, Horcajada JP. Oral and intravenous fosfomycin in complicated urinary tract infections. Rev Esp Quimioter. 2019;32:37–44.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Mirsalehian A, Kalantar-Neyestanaki D, Nourijelyani K, et al. Detection of AmpC-β-lactamases producing isolates among carbapenem resistant P. aeruginosa isolated from burn patient. Iran J Microbiol. 2014;6(5):306–310.
   PubMedGoogle Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing, document M100. 27th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
   Google Scholar
• van der Zwaluw K, de Haan A, Pluister GN, et al. The carbapenem inactivation method (CIM), a simple and low-cost alternative for the carba NP test to assess phenotypic carbapenemase activity in gram-negative rods. PLoS One. 2015;10(3):e0123690.
   PubMed Web of Science ®Google Scholar
• Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol. 2006;44(9):3139–3144.
   PubMed Web of Science ®Google Scholar
• Sachdeva R, Sharma B, Sharma R. Evaluation of different phenotypic tests for detection of metallo-β-lactamases in imipenem-resistant Pseudomonas aeruginosa. J Lab Phys. 2017;9(4):249–253.
   Google Scholar
• Mazzariol A, Mammina C, Koncan R, et al. A novel VIM-type metallo-beta-lactamase (VIM-14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit. Clin Microbiol Infect. 2011;17(5):722–724.
   PubMed Web of Science ®Google Scholar
• Bosnjak Z, Bedenić B, Mazzariol A, et al. VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from zagreb, Croatia. Scand J Infect Dis. 2010;42(3):193–197.
   PubMed Web of Science ®Google Scholar
• Bubonja-Sonje M, Matovina M, Skrobonja I, et al. Mechanisms of carbapenem resistance in multidrug-resistant clinical isolates of Pseudomonas aeruginosa from a Croatian hospital. Microb Drug Resist. 2015;21(3):261–269.
   PubMed Web of Science ®Google Scholar
• Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol. 2002;3(2):117–127.
   PubMedGoogle Scholar
• Doern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124–4128.
   PubMed Web of Science ®Google Scholar
• FDA. Ceptaz (ceftazidime for injection) [Internet]. England, GlaxoSmithKline, Research Triangle Park, NC 27709; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/050646s014lbl.pdf.
   Google Scholar
• FDA. Gentamicin injection [Internet]. Fresenius Kabi USA, LCC. 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062366s033lbl.pdf.
   Google Scholar
• FDA. Amikacin Sulfate [Internet]. Abbott laboratories, North Chicago, IL 60064, USA; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/64146AP.PDF.
   Google Scholar
• FDA. Primaxin (imipenem and cilastatin) for injection, for intravenous use [Internet]. Merck&Co., Inc.Whitehouse Station, NJ. USA. 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050587s074lbl.pdf.
   Google Scholar
• Car H. In vitro synergy and postantibiotic effect of colistin combinations with meropenem and vancomycin against gram negative bacteria with multiple carbapenem resistance mechanisms. Vol. 198. Osijek, Croatia: Josip Juraj Strossmayer Univ Osijek; 2020.
   Google Scholar
• Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143–151.
   PubMed Web of Science ®Google Scholar
• Moni M, Sudhir S, Dipu TS, et al. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an indian hospital with high endemic rates of multidrug-resistant gram-negative bacterial infections: a prospective observational study. Int J Infect Dis. 2020;100:497–506.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Hickman RA, Forsberg P, et al. Evaluation of double-and triple-antibiotic combinations for VIM-and NDM-Producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58(3):1757–1762.
   PubMed Web of Science ®Google Scholar
• Silva F, Lourenço O, Queiroz JA, et al. Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye. J Antibiot (Tokyo). 2011;64(4):321–325.
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother. 2003;51(4):857–864.
   PubMed Web of Science ®Google Scholar
• Bundtzen RW, Gerber AU, Cohn DL, et al. Postantibiotic suppression of bacterial growth. Rev Infect Dis. 1981;3(1):28–37.
   PubMedGoogle Scholar
• Craig WA. The postantibiotic effect. Clin Microbiol Newsl. 1991;13(16):121–124.
   Google Scholar
• Munckhof WJ, Borlace G, Turnidge JD. Postantibiotic suppression of growth of erythromycin A-susceptible and-resistant gram-positive bacteria by the ketolides telithromycin (HMR 3647) and HMR 3004. Antimicrob Agents Chemother. 2000;44(6):1749–1753.
   PubMed Web of Science ®Google Scholar
• Bedenić B, Beader N, Godič-Torkar K, et al. Postantibiotic effect of colistin alone and combined with vancomycin or meropenem against Acinetobacter spp. with well defined resistance mechanisms. J Chemother. 2016;28(5):375–382.
   PubMed Web of Science ®Google Scholar
• Li RC, Tang MC. Post-antibiotic effect induced by an antibiotic combination: influence of altered susceptibility to individual components. J Antimicrob Chemother. 2005;55(4):583–586.
   PubMed Web of Science ®Google Scholar
• Ferrara A, Santos C, Dos Cimbro M, et al. Postantibiotic effect of meropenem in combination with gentamicin or sparfloxacin on gram-positive and gram-negative organisms. Clin Microbiol Infect. 1998;4(8):431–435.
   Google Scholar
• Codjoe FS, Donkor ES. Carbapenem resistance: a review. Med Sci. 2018;6:1.
   Google Scholar
• Di X, Wang R, Liu B, et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant pseudomas aeruginosa. J Antibiot (Tokyo). 2015;68(9):551–555.
   PubMed Web of Science ®Google Scholar